Inside IPEC: IPEC Tackles Monographs, Impurities, Particles, and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside IPEC: IPEC Tackles Monographs, Impurities, Particles, and More
As the excipient supply chain becomes more complex, industry must up the ante to comply with new standards and regulations.


Pharmaceutical Technology
pp. 49-50

Nanotechnology

A relatively new area of the federation's work is an attempt to monitor nanotechnology developments with respect to their impact on excipient monographs, as well as in the context of draft guidance on nanotechnology published by FDA in June 2011 (1). A major concern for the excipient industry is that excipients not developed for their "nano" properties may fall within particle-size range definitions being discussed for "nano" materials and therefore may be required to comply with potential new safety-assessment requirements.

Particularly, the federation is looking to change the particle-size range expansion from less than 100 nm to a range of 100 nm to 1 g. There is a need for global harmonization of these initiatives within US, Europe, and other countries. IPEC has worked with various trade associations to submit comments regarding these issues to FDA in response to their draft guidance.

Overall, the federation's 2011 work plan is full, but much remains to be done. Many of the initiatives mentioned here will continue into 2012, as will the organization's member-expansion program.

Acknowledgment

The author would like to thank David S. Schoneker with IPEC–Americas for his contribution to this article.

Patricia Rafidison is chair of the IPEC Federation, and the global regulatory affairs and compliance manager at Dow Corning.

Reference

1. FDA, Guidance for Industry: Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology (FDA, Rockville, MD, June 2011).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here